Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (144)	6/16/1999 1:07:00 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 370

Vion: Preclinical Results For Tapet Tech Promising Dow Jones Newswires NEW HAVEN, Conn. -- Preclinical data from mice studies of Vion Pharmaceuticals Inc.'s (VION) VNP20009, the first bacterial candidate under the company's Tapet technology, suggests that VNP20009 is capable of migrating from injected tumors to distal non-injected tumors. In a press release Monday, the biopharmaceutical company said there is "great promise in the Tapet development program." Preclinical studies also demonstrate in animals that direct intratumoral administration of VNP20009 inhibited the growth of injected tumors, uninjected tumors and lung metastases. Tapet, which stands for tumor amplified protein expression therapy, uses bioengineered bacterial vectors that exhibit increased replication in solid tumors in preclinical tests. VNP20009 bacteria are unarmed Tapet vectors developed for Phase I clinical safety studies. Combined with earlier, "encouraging" data gathered in mice treated intravenously, Vion said it believes it can enter clinical testing with a "viable product candidate." After recently submitting an Investigational New Drug application with the Food and Drug Administration, Vion said it is working under an open IND status to prepare for and begin Phase I clinical safety studies of Tapet. Vion Pharmaceuticals' Nasdaq-listed shares closed Tuesday at 5 7/16, down 1/4 or 4.4% on below-average average. On Monday the stock closed at 5 11/16, up 15/32, or 9%.